Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

por Kondo, Shunsuke, Tajimi, Masaomi, Funai, Tomohiko, Inoue, Koichi, Asou, Hiroya, Ranka, Vinay Kumar, Wacheck, Volker, Doi, Toshihiko
Publicado 2020